Equities

Roche Holding AG

0QQ6:LSE

Roche Holding AG

  • Price (CHF)258.20
  • Today's Change1.40 / 0.55%
  • Shares traded110.00
  • 1 Year change-17.62%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 09:02 BST.
More ▼

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)58.72bn
  • Net income in CHF11.50bn
  • Incorporated1966
  • Employees103.61k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QQ6:LSE since
announced		Transaction
value
LumiraDx International LtdAnnounced29 Dec 202329 Dec 2023Announced6.50%--
LumiraDx Group LtdAnnounced29 Dec 202329 Dec 2023Announced6.50%295.00m
Carmot Therapeutics IncDeal completed04 Dec 202304 Dec 2023Deal completed7.76%3.10bn
Data delayed at least 20 minutes, as of May 17 2024 09:02 BST.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.